Arranon is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Nelarabine.
Product ID | 0078-0683_3616a9ae-3037-42aa-825f-78628639e3e9 |
NDC | 0078-0683 |
Product Type | Human Prescription Drug |
Proprietary Name | Arranon |
Generic Name | Nelarabine |
Dosage Form | Injection |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2016-10-05 |
Marketing Category | NDA / NDA |
Application Number | NDA021877 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | NELARABINE |
Active Ingredient Strength | 5 mg/mL |
Pharm Classes | Nucleoside Metabolic Inhibitor [EPC],Nucleic Acid Synthesis Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2016-10-05 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA021877 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2016-10-05 |
Marketing Category | NDA |
Application Number | NDA021877 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2019-08-02 |
Ingredient | Strength |
---|---|
NELARABINE | 5 mg/mL |
SPL SET ID: | fffa5d75-0dba-4ad7-a252-5f60fa28489a |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0683 | Arranon | nelarabine |
43598-142 | Nelarabine | Nelarabine |
70710-1726 | Nelarabine | Nelarabine |
70710-1839 | Nelarabine | Nelarabine |
70771-1685 | Nelarabine | Nelarabine |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ARRANON 78325294 2901813 Live/Registered |
NOVARTIS PHARMA AG 2003-11-10 |
ARRANON 78226967 2877259 Dead/Cancelled |
GLAXOSMITHKLINE LLC 2003-03-18 |